Systemic Lupus Erythematosus Market 2022 - Market Size & Forecast, Industry Trends, Manufacturers Analysis, & Opportunities 2030

The global systemic lupus erythematosus market size is expected to register growth at a CAGR of 6.0% over the forecast period of 2022-2030.

Systemic lupus erythematosus (SLE), also commonly known as lupus, is a complex chronic autoimmune disease which results in the inflammation of tissues in the body. Some of the common symptoms of the disease include; fatigue, fever, skin rashes, joint pain, malaise, and temporary loss of cognitive ability.  These signs and symptoms can vary between individuals.

The disease affects connective tissues that provide strength and flexibility to body structures and multiple organs and structures, including the kidneys, skin, joints, lungs, central nervous system, and blood-forming (hematopoietic) system. Although the predominant cause of the disease is still unknown, few studies have revealed a complex genetic and hormonal basis. The intensity of the disease ranges from moderate to severe and is more common in women, typically affecting individuals in the age group of 25 to 45. At least 5.0 million people worldwide are reported to suffer from a form of lupus. Therapies in development for the disease emphasize on a wide variety of targets.

GROWTH DRIVERS:

Factors such as the burgeoning prevalence of autoimmune diseases globally; the rising worldwide awareness about lupus and SLE treatments; the increasing arrival of key pipeline agents which promise higher efficacy than the currently existent therapies; the rapid introduction of new biological therapies and the escalating R&D investment in SLE drugs are primarily driving the growth of the global systemic lupus erythematosus market.

The GlaxoSmithKline company currently has the highest overall number of completed clinical trials for SLE, with 30 trials, followed by AstraZeneca. Till date, GlaxoSmithKline’s Benlysta (2011) is the only drug to have launched for SLE in the last 50 years. The number of therapies in development for moderate to severe SLE without active renal disease and/or lupus nephritis is also increasing, which is presenting ample opportunities for the growth of the market for the upcoming years.

Additionally, biologics for autoimmune conditions are increasingly gaining physicians approval and confidence as they enhance treatment for the disease to a large degree. Also, some of the key pipeline biologics that are undergoing phase III clinical trials are expected to set foot in the market in the next few years and are anticipated to fuel the market as these drugs could target the lupus nephritis patient subset with more effective alternatives. The demand for Benlysta is also increasing, especially in the matured regions. All these factors are expected to significantly contribute to the growth of the market in the upcoming years.

Furthermore, factors such as the existence of high level of unmet needs in the SLE market for therapies that can reduce the use of corticosteroids and enhance the quality of life of patients, the increasing number of key efforts by manufacturers on the development of biologics with higher efficacy and the increasing number of big players entering the market with promising therapies are anticipated to further propel the growth of the market during the forecast period.

However, factors such as low to moderate efficacy of Benlysta towards patients diagnosed with severe systemic lupus erythematosus (SLE), including lupus nephritis, the dearth of understanding regarding the pathogenesis of the disease and use of off-label drugs may hamper the growth of the market to certain extent during the forecast timeframe.

SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SEGMENTATION:

By Drug Classes:

·         NSAID

·         Corticosteroids

·         Antimalarials

·         Immunosuppressants

·         Biologics

 

By Route of Administration:

·         Oral

·         Intravenous

·         Subcutaneous

·         Topical

 

By Distribution Channel:

·         Retail Pharmacies

·         Hospitals

·         Online Pharmacies

 

By Region:

·         North America

·         Europe

·         Asia Pacific

·         Latin America

·         Middle East and Africa

 

Based on drug classes, the immunosuppressants segment held the largest share in the market in 2021. The segment is expected to continue to lead the market during the forecast period due to factors such as the growing worldwide adoption of methotrexate and other immunosuppressants due to their low cost and high accessibility. However, the biologics segment is projected to attain the highest growth rate of 13.0% during the forecast period of 2022-2030.

Based on route of administration, the oral segment held the commanding position with 54.0% share in the market in 2021 followed by the intravenous segment. The trend is anticipated to continue over the forecast period.

Based on distribution channel, the hospitals segment held the largest share in the market in 2021, followed by the retail pharmacies segment. The segments are expected to retain their hold over the market during the forecast period of 2022-2030.

 

REGIONAL OUTLOOK:

The North American region accounted for the largest share of 30.0% in the global systemic lupus erythematosus market in 2021. The region is expected to maintain this trend and is anticipated to witness expansion a CAGR of 8.5% during the forecast period of 2022-2030. Factors such as the soaring prevalence of SLE in the region; the availability and presence of reimbursement policies, better healthcare infrastructure and easy accessibility to biologics in the region; the growing healthcare spending by the people in the region coupled with the proliferating awareness regarding the disease and the increasing number of SLE clinical trials in the U.S. are predominantly contributing to the growth of the market in the region. The U.S. is the major contributor to the growth of the market in the region.

 

The European region accounted for the second largest share in the global systemic lupus erythematosus market in 2021. The region is expected to further retain its position and is expected to register a CAGR of 5.6% over the forecast period. This can be attributed to the high rate of approval of biologics and therapies for SLE and related conditions and the increasing adoption of belimumab in the region along with several other factors. The Germany is the leading contributor to the market in the European region.

 

The Asia Pacific region held the third-largest share and is projected to witness the fastest growth in the market during the forecast period. The growth of the market in the region can attributed to the surging prevalence of the disease in the region, the raising awareness regarding the disease among the population in the emerging countries of the region, the rapidly developing medical infrastructure coupled with the increasing healthcare expenditure and medical tourism in the region. Moreover, the proliferating cases of asthma and the changing lifestyles of people in the region are also significantly contributing towards the growth of the market in the region. South Korea stands as the leading contributor to the market growth in the region.

 

The Latin America and Middle East and African regions hold the least share in the market. They are expected to witness sluggish growth in the forecast period due to the low rheumatologist to population ratio and the low accessibility of therapies to patients due to their price and unfavorable reimbursement policies in the regions.

 

KEY COMPANIES IN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET:

·         Pfizer

·         Novartis

·         Bayer

·         Amgen Inc.

·         Bristol-Myers Squibb Company

·         GlaxoSmithKline PLC

·         Immunomedics Inc.

·         Johnson & Johnson

·         MedImmune LLC

·         Merck Serono GmbH

·         Sanofi SA

·         Teva Pharmaceutical Industries Ltd.

·         UCB SA

·         F. Hoffmann-La Roche Ltd.

·         Hansa Medical Ab

·         Harbor Biosciences

·         Other Players